Key Highlights

  • Cash, cash equivalents, bank deposits and Money Market funds were $1.0 million as of June 30, 2026.
  • The company completed a private Placement with certain accredited investors for aggregate gross consideration of about $10.0 million.
  • Research and development expenses were $2.0 million for the period.
  • General and administrative expenses were $4.5 million for the period.

Apollomics (NASDAQ:APLM) reported financial results for the first half of 2026, including cash, cash equivalents, bank deposits and money market funds of $1.0 million as of June 30, 2026.

Cash and Financing

Cash, cash equivalents, bank deposits and money market funds were $1.0 million as of June 30, 2026, according to the company's report.

The report presents the balance as of the end of the second quarter, which is the most recent Balance Sheet date in the results.

Operating Expenses

Research and development expenses were $2.0 million, including share-based compensation. The company reported R&D expenses of $4.6 million for the comparison period in the first half of 2025, including share-based compensation.

General and administrative expenses were $4.5 million, including share-based compensation. The comparison figure for the prior-year first half was $14.5 million, including share-based compensation, according to the company's report.

Final Word

Apollomics reported cash, cash equivalents, bank deposits and money market funds of $1.0 million as of June 30, 2026, a private placement of about $10.0 million, Research and Development expenses of $2.0 million and general and administrative expenses of $4.5 million.